dactinomycin has been researched along with n(alpha)-(4-amino-4-deoxy-n(10)--methylpteroyl-n(epsilon)-4'-fluoresceinthiocarbamoyl)-l-lysine trihydrate in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Camarata, M; Cooke, R; Dancy, G; Krell, J; Kwan, A; O'Nions, J; Savage, P; Seckl, MJ; Short, D; Swerdlow, A | 1 |
1 other study(ies) available for dactinomycin and n(alpha)-(4-amino-4-deoxy-n(10)--methylpteroyl-n(epsilon)-4'-fluoresceinthiocarbamoyl)-l-lysine trihydrate
| Article | Year |
|---|---|
Effects of single-agent and combination chemotherapy for gestational trophoblastic tumors on risks of second malignancy and early menopause.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Cohort Studies; Cyclophosphamide; Dactinomycin; Etoposide; Female; Follow-Up Studies; Gestational Trophoblastic Disease; Humans; Incidence; Kaplan-Meier Estimate; Menopause, Premature; Methotrexate; Middle Aged; Neoplasms, Second Primary; Odds Ratio; Pregnancy; Risk Assessment; Risk Factors; Uterine Neoplasms; Vincristine; Young Adult | 2015 |